Anti‐Kell in Pregnancy

Leggat, Hilary; Gibson, Jonathan; Barron, S. L.; Reid, M M

doi:10.1111/j.1471-0528.1991.tb13522.x

Cited by 25 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fetal anaemia as a result of Kell antibodies is considered to be caused more by suppression of erythropoiesis than by haemolysis of red cells [1,14]. Kell‐affected fetuses have lower bilirubin levels and reticulocyte counts than their Rh D counterparts [15–17]. Intrauterine transfusion (IUT) has been used with success in anti‐K‐affected fetuses [14,18].…”

Section: Discussionmentioning

confidence: 99%

Treatment with plasmapheresis and intravenous immunoglobulin in pregnancies complicated with anti‐PP₁P^k or anti‐K immunization: a report of two patients

et al. 2001

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment with plasmapheresis and intravenous immunoglobulin in pregnancies complicated with anti‐PP₁P^k or anti‐K immunization: a report of two patients

et al. 2001

View full text Add to dashboard Cite

show abstract

“…Approximately 10% of transfusions are mismatched for KEL1/KEL2, with anti‐KEL1 as well as anti‐KEL2 leading to hemolysis of incompatible transfused RBCs or of incompatible fetal RBCs. In fact, KEL alloantibodies are a leading cause of transfusion‐ and pregnancy‐associated morbidity and mortality today 28‐33…”

mentioning

confidence: 99%

Transfusion of murine red blood cells expressing the human KEL glycoprotein induces clinically significant alloantibodies

et al. 2013

View full text Add to dashboard Cite

Background Red blood cell (RBC) alloantibodies to non-self antigens may develop following transfusion or pregnancy, leading to morbidity and mortality in the form of hemolytic transfusion reactions or hemolytic disease of the newborn. A better understanding of the mechanisms of RBC alloantibody induction, or strategies to mitigate the consequences of such antibodies, may ultimately improve transfusion safety. However, such studies are inherently difficult in humans. Study Design and Methods We recently generated transgenic mice with RBC specific expression of the human KEL glycoprotein, with the KEL2 or KEL1 antigens. Herein, we investigate recipient alloimmune responses to transfused RBCs in this system. Results Transfusion of RBCs from KEL2 donors into wild type recipients (lacking the human KEL protein but expressing the murine KEL orthologue) resulted in dose dependent anti-KEL glycoprotein IgM and IgG antibody responses, enhanced by recipient inflammation with poly (I:C). Boostable responses were evident upon repeat transfusion, with morbid appearing alloimmunized recipients experiencing rapid clearance of transfused KEL2 but not control RBCs. Although KEL1 RBCs were also immunogenic following transfusion into wild type recipients, transfusion of KEL1 RBCs into KEL2 recipients or vice versa failed to lead to detectable anti-KEL1 or anti-KEL2 responses. Conclusions This murine model, with reproducible and clinically significant KEL glycoprotein alloantibody responses, provides a platform for future mechanistic studies of RBC alloantibody induction and consequences. Long term translational goals of these studies include improving transfusion safety for at risk patients.

show abstract

“…1,3,4 The Kell blood group is important in clinical medicine because antibodies to the principal antigen, K1, cause T both life-threatening transfusion reactions and severe alloimmune anemia in Kell-positive fetuses and newborn infants. 5,6 Alloimmunization occurs when Kell-negative women, who do not have the K1 antigen on their red cells, become sensitized by carrying a Kell-positive fetus to produce alloantibodies that may cross the placenta and cause fetal anemia in a Kell-positive, but not a Kell-negative, fetus.…”

mentioning

confidence: 99%

Inhibition of Erythroid Progenitor Cells by Anti-Kell Antibodies in Fetal Alloimmune Anemia

Vaughan

Manning²,

Warwick³

et al. 1998

N Engl J Med

254

View full text Add to dashboard Cite

show abstract

Anti‐Kell in Pregnancy

Cited by 25 publications

References 6 publications

Treatment with plasmapheresis and intravenous immunoglobulin in pregnancies complicated with anti‐PP₁P^k or anti‐K immunization: a report of two patients

Treatment with plasmapheresis and intravenous immunoglobulin in pregnancies complicated with anti‐PP₁P^k or anti‐K immunization: a report of two patients

Transfusion of murine red blood cells expressing the human KEL glycoprotein induces clinically significant alloantibodies

Inhibition of Erythroid Progenitor Cells by Anti-Kell Antibodies in Fetal Alloimmune Anemia

Contact Info

Product

Resources

About

Anti‐Kell in Pregnancy

Cited by 25 publications

References 6 publications

Treatment with plasmapheresis and intravenous immunoglobulin in pregnancies complicated with anti‐PP1Pk or anti‐K immunization: a report of two patients

Treatment with plasmapheresis and intravenous immunoglobulin in pregnancies complicated with anti‐PP1Pk or anti‐K immunization: a report of two patients

Transfusion of murine red blood cells expressing the human KEL glycoprotein induces clinically significant alloantibodies

Inhibition of Erythroid Progenitor Cells by Anti-Kell Antibodies in Fetal Alloimmune Anemia

Contact Info

Product

Resources

About

Treatment with plasmapheresis and intravenous immunoglobulin in pregnancies complicated with anti‐PP₁P^k or anti‐K immunization: a report of two patients

Treatment with plasmapheresis and intravenous immunoglobulin in pregnancies complicated with anti‐PP₁P^k or anti‐K immunization: a report of two patients